Centessa Pharmaceuticals plc: insider trades · United States · SEC (Form 4)

About Centessa Pharmaceuticals plc

Centessa Pharmaceuticals plc is a clinical-stage biopharmaceutical company listed in the United States on the Nasdaq under the ticker CNTA. Although it is organized as a UK public limited company, its operating footprint and investor messaging are clearly transatlantic, with key hubs in Boston and London. For French, Belgian and Swiss investors, Centessa is best viewed as a high-risk, high-upside biotech story: valuation is driven less by current revenues than by clinical execution, regulatory milestones, and strategic optionality. The company was formed in October 2020 around an “asset-centric” operating model intended to develop focused therapeutic programs with better capital efficiency than the traditional broad-platform biotech approach. Over time, Centessa has increasingly concentrated its strategic narrative around orexin biology. Its current core business is the discovery and development of orally administered orexin receptor 2 (OX2R) agonists designed to treat sleep-wake disorders, especially narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia. Centessa’s lead asset is ORX750, a clinical-stage candidate positioned by management as potentially best-in-class. The pipeline also includes ORX142 and ORX489, which expand the opportunity set into broader neurological, neurodegenerative, and neuropsychiatric indications. In addition, the company retains an earlier-stage immuno-oncology platform built on its proprietary LockBody® technology, although the equity case is now overwhelmingly centered on orexin. From a competitive perspective, Centessa operates in a specialized and scientifically demanding segment where differentiation depends on selectivity, tolerability, oral convenience, and the quality of clinical data. It competes in a space with meaningful unmet medical need and substantial commercial interest, but it remains a pre-revenue company and therefore depends on successful trial readouts, regulatory progress, and continued financing discipline. That makes the stock highly sensitive to both positive data and dilution risk. Recent corporate developments are important. In 2025, Centessa reported progress across its OX2R pipeline, including updates on ORX750 and ORX142, and it also completed a significant Nasdaq ADS offering to strengthen its balance sheet. Most notably, in March 2026, Centessa announced a definitive agreement to be acquired by Eli Lilly, a major strategic event that underscores the perceived value of the company’s orexin platform. For equity investors, CNTA is therefore a name to monitor closely around insider activity, trial catalysts, and M&A developments, all within the United States public-market context on Nasdaq.